Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017

Wednesday, January 31, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017

NEW YORK, Jan. 30, 2018 /PRNewswire/ -- Read the full report: https://www.reportlinker.com/p05298286 SummaryCervical

intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). There are a total of 163 products in development for this indication, by 118 companies and 25 academic institutions. Key companies operating in this pipeline space include Advaxis, F. Hoffmann-La Roche, GlaxoSmithKline, Kite Pharma, MedImmune and Pfizer.The most prominent targets in the cervical cancer pipeline are HPV proteins there are a number of products in the pipeline targeting HPV protein E7 and HPV protein E6. Other common targets in the pipeline include vascular endothelial growth factor A and programmed cell death protein 1.Vaginal cancer is a rare cancer that causes symptoms such as watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. There are a total of 6 products in development for this indication, by 6 companies. The companies operating in this pipeline space are ISA Pharmaceuticals, MedImmune, Ology Bioservices, Ono Pharmaceutical, Oryx GmbH & Co KG and Taiwan Liposome Company.Finally, Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. There are a total of 5 products in development for this indication, by 5 companies. The five companies operating in this pipeline are Cutanea Life Sciences, ISA Pharmaceuticals, MedImmune, Ono Pharmaceutical and Oryx GmbH & Co KGThe report "Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017" provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervical Cancer, Vaginal Cancer and Vulvar Cancer, and features dormant and discontinued projects.Scope- Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationRead the full report: https://www.reportlinker.com/p05298286 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com  US: (339)-368-6001 Intl: +1 339-368-6001 

Cision View original content:http://www.prnewswire.com/news-releases/lower-female-reproductive-system-cancers-drug-development-pipeline-review-2017-300590537.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store